PWMS News Search Results

Back to NewsWire HomeBack to  Back to PeopleWithMS NewsWire

May 2008 Off the Wire . . .




Interferon Failers who switch to Copaxone do well

Submitted by art on Fri, 2008-05-02 07:45.

Teva Pharmaceutical Industries has reported encouraging results from a three-year study evaluating relapsing-remitting multiple sclerosis patients who failed first-line monotherapy and switched treatments.

The results demonstrated that patients who switched from interferon beta (IFN beta) to Copaxone (glatiramer acetate injection) experienced a 77% reduction in annualized relapse rates (0.63 to 0.14). In addition, these patients did not progress significantly in their disability as measured by expanded disability status scale (EDSS).

E-Mail the NewsWire e-mail the NewsWire ! ! ! - Handpainted and Customized Canes
 with any news items you discover 

copyright 2003